Fenbid- Sino-US GSK another crisis-.docVIP

 PAGE \* MERGEFORMAT 10 Fenbid: Sino-US GSK another crisis? The end of 2000, the U.S. Food and Drug Administration issued a public health bulletin, demanded that the U.S. manufacturers take the initiative to stop selling PPA-containing products, followed by China’s State Drug Administration at a later time to release a ‘moratorium on the use and sale of benzene in propanol amine pharmaceutical preparations notice ‘, was suspended in 15 kinds of use and sale of medicines containing PPA in the United States included SmithKline production Contac and Kant two products. Sino-US GSK faces a huge crisis, but later, as we know, the United States that GSK has successfully defused the crisis. Recently, the U.S. Food and Drug Administration (FDA) warning to all non-steroidal anti-inflammatory drugs have the potential cardiovascular risks of GlaxoSmithKline’s Fenbid United States has been warning of the drug because it is larger in sales of single items, this event spreading rapidly in China, GSK has once again pushed the Sino-US wind sharp waves mouth. So, non-steroidal anti-inflammatory drugs for warning events on Fenbid What does it mean? How will the Sino-US SmithKline address this crisis? This event will be how to develop? For relevant competitive products whether it is a marketing opportunity? From the non-steroidal anti-inflammatory drugs warning to Fenbid event April 7, the U.S. Food and Drug Administration (FDA) released the latest of all anti-inflammatory analgesic medication guide statements, the integration of existing research data, all the non-steroidal anti-inflammatory drugs have the potential cardiovascular risk. On these drugs including the ‘Fenbid’ and so on. FDA has asked manufacturers of these drugs in their instructions to add boxed warning. In the April 7 years of this statement, FDA refer to all the market of non-steroidal anti-inflammatory analgesics there may be cardiovascular safety issues, rather than one or two drugs from unique. All the an